# A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease

> **NCT07720648** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Beijing Kanghong Biological Medicine Co., Ltd.** · enrollment: 117 (estimated)

## Conditions studied

- Thyroid Eye Disease

## Interventions

- **DRUG:** KHN939
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07720648
- **Lead sponsor:** Beijing Kanghong Biological Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2027-05
- **Final completion:** 2027-06
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2026-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07720648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07720648, "A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07720648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*